Kuan-Lin Chen

Kuan-Lin Chen

Auto-generated profile, based on publicly available information

Kuan-Lin Chen

Taipei Veterans General Hospital

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in The American Journal of Medicine
Verified
Journal Article
Closed access
KCKuan-Lin Chen
Kuan-Lin Chen
Shyh-Jen WangShyh-Jen Wang
Shyh-Jen Wang
CCChien Chuang
Chien Chuang
LHLi-Ying Huang
Li-Ying Huang
FCFang-Yao Chiu
Fang-Yao Chiu
WCWei-Ming Chen
Wei-Ming Chen

6 March 2025 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
KCKuan-Lin Chen
Kuan-Lin Chen
CCCheng-Fong Chen
Cheng-Fong Chen
PWPo-Kuei Wu
Po-Kuei Wu
PWPai-Han Wang
Pai-Han Wang
TCTain-Hsiung Chen
Tain-Hsiung Chen
WCWei-Ming Chen
Wei-Ming Chen
Background: When managing aggressive giant cell tumor of bone (GCTB) around the knee joint, surgeons are often caught in a dilemma when determining whether to perform marginal excision or intralesional curettage. The purpose of this study was to report the long-term results of different treatment strategies in our institute. Methods: We retrospectively reviewed 64 eligible cases (34 female and 30 male) with a GCTB (37 in the distal femur, 27 in the proximal tibia) treated from 2002 to 2013. Forty patients received intralesional curettage (group A). Twenty-four received marginal excision of the tumor, with 18 of them undergoing reconstruction with unicondylar osteoarticular allograft (UOA) (group B) and 6 receiving arthroplasty reconstruction (group C). The minimum follow-up was 8 years, and the oncological status, clinical outcomes, and cartilage condition were analyzed. Results: Tumor recurrence was most common in group A (10 of 40, 25.0%), followed by group B (1 of 18, 5.6%) and group C (0 of 6). Eleven patients in group A (27.5%) and 6 in group B (33.3%) developed osteoarthritis (Kellgren-Lawrence grade 3 or 4). Five patients in group A (12.5%) and 3 patients in group B (16.7%) received total knee arthroplasty. Risk factors for the development of osteoarthritis in group A included a centrally located tumor, tumor length of >6 cm, a tumor-cartilage distance of ≤3 mm, and >50% subchondral bone involvement. In group B, osteoarthritis mostly resulted from postoperative complications. The mean Musculoskeletal Tumor Society (MSTS) score was 87.9 in group A, 84.8 in group B, and 93.3 in group C. Conclusions: Although intralesional curettage preserved cartilage and resulted in better function, it was associated with a higher tumor recurrence rate in our series. For advanced tumors close to the articular cartilage with significant subchondral bone involvement, marginal excision with UOA reconstruction might be a viable alternative. Arthroplasty should be reserved for patients who have bicondylar involvement with severe bone and cartilage loss making cartilage preservation impossible. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

29 January 2026 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
LZLeo Zalikha
Leo Zalikha
KCKuan-Lin Chen
Kuan-Lin Chen
APAlexa K. Pius
Alexa K. Pius
MSMarcel Sanchez
Marcel Sanchez
IZIsabella Zaniletti
Isabella Zaniletti
JHJames I. Huddleston
James I. Huddleston
Background: The U.S. Centers for Medicare & Medicaid Services (CMS) has set the substantial clinical benefit (SCB) for the Knee injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS-JR) after primary total knee arthroplasty (TKA) at 20 points. We aimed to determine the percentages of patients who achieved the minimal clinically important difference (MCID) and the SCB for KOOS-JR at 1 year following TKA and to evaluate factors associated with benchmark achievement. Methods: We queried the American Joint Replacement Registry (AJRR) and screened 1,284,404 primary TKA cases performed from 2018 to 2023. We determined attainment of the KOOS-JR distribution-based MCID (7.5), anchor-based MCID (14), and SCB (20) at 12 months by each patient. Associations of covariates with the achievement of the MCIDs and the SCB were evaluated using a generalized linear model for binary outcomes that accounted for clustering within institutions. Unadjusted and adjusted odds ratios (ORs) for the outcomes of interest with 95% confidence intervals (CIs) were reported. Covariates included the preoperative KOOS-JR, sex, race or ethnicity, body mass index (BMI), Charlson Comorbidity Index (CCI), fixation type, use of technology, year of the procedure, region, institution type, teaching status, and number of beds. Results: Linked scores were recorded by 64,773 patients. The mean patient age was 68.35 ± 8.60 years, 61.29% of patients were female, and 83.52% of patients were non-Hispanic White. The KOOS-JR threshold achievement rate was 86.8% for the calculated distribution-based MCID, 76.5% for the anchor-based MCID, and 65.7% for the SCB. Patients with higher preoperative scores (adjusted OR, 0.93 [95% CI, 0.93 to 0.93]; p < 0.001), Asian patients (adjusted OR, 0.59 [95% CI, 0.46 to 0.74]; p < 0.001), Black patients (adjusted OR, 0.55 [95% CI, 0.49 to 0.62]; p < 0.001), Hispanic patients (adjusted OR, 0.71 [95% CI, 0.51 to 0.99]; p = 0.042), non-Hispanic patients of other races (adjusted OR, 0.84 [95% CI, 0.74 to 0.95]; p = 0.007), male patients (adjusted OR, 0.89 [95% CI, 0.85 to 0.94]; p < 0.001), and patients with higher BMI (adjusted OR, 0.93 [95% CI, 0.87 to 0.99]; p = 0.025) showed lower odds of achieving the SCB. A CCI of ≥5 was additionally found to be associated with lower odds of achieving the distribution-based MCID (adjusted OR, 0.89 [95% CI, 0.79 to 0.99]; p = 0.032) and anchor-based MCID (adjusted OR, 0.89 [95% CI, 0.81 to 0.97]; p = 0.012). Conclusions: The CMS relatively arbitrarily defined the SCB at a value that is too high for an operation that routinely yields >80% patient satisfaction. Level of Evidence: Prognostic Level II . See Instructions for Authors for a complete description of levels of evidence.

1 October 2025 in Journal of Experimental Orthopaedics
Verified
Journal Article
Open access
YTYu‐Hung Tian
Yu‐Hung Tian
KCKuan‐Lin Chen
Kuan‐Lin Chen
PWPai‐Han Wang
Pai‐Han Wang
PWPo-Kuei Wu
Po-Kuei Wu
CCCheng-Fong Chen
Cheng-Fong Chen
WCWei-Ming Chen
Wei-Ming Chen
Purpose: Isolated patellofemoral osteoarthritis (PFOA) is a degenerative condition, typically presenting as anterior knee pain. For patients who are refractory to conservative treatment, patellofemoral arthroplasty (PFA) is a viable surgical option. Appropriate patient selection is fundamental to achieving favourable long‐term outcomes. Large multicenter and registry studies have reported outcomes of PFA (under 0.45%–2% utilization). Howevever, because of the heterogenicity of indications and surgeons, those findings may not be transferable to individual surgeon practices. This study aimed to evaluate the utilization and long‐term survival of PFA within a high‐volume, single‐surgeon arthroplasty practice. Methods: This retrospective study included consecutive cases of Patellofemoral arthroplasties performed between 2012 and 2014. Patients with prior ipsilateral knee surgery, patellar instability, or less than 10 years of follow‐up were excluded. The number of primary knee arthroplasties performed within the same period was collected. Radiographic assessments included Kellgren–Lawrence grading, Iwano grading, Insall‐Salvati ratio, Dejour classification, medial proximal tibial angle, joint line convergence angle, sulcus angle and anatomical lateral distal femoral angle. Implant survival rates were evaluated over a 10‐year follow‐up period. Results: A total of 37 patients (50 patellofemoral arthroplasties) who underwent PFA for isolated PFOA were included, alongside 2556 primary knee arthroplasties. PFAs accounted for 2.0% of the primary knee arthroplasties performed during the study period. All patients were classified as Iwano grade IV preoperatively. The 10‐year survival rate was 86.0%. All seven PFA failures were due to progression of tibiofemoral osteoarthritis and were converted to total knee arthroplasty. Conclusions: PFA demonstrated a 10‐year implant survival rate of 86.0% when performed under strict selection criteria in a high‐volume arthroplasty centre. Achieving optimal outcomes requires careful patient selection, surgical proficiency and alignment with patient expectations. Further prospective studies are warranted to better evaluate long‐term functional outcomes after PFA. Level of Evidence: Level III, retrospective cohort study.


8 July 2026 in Journal of Orthopaedic Surgery and Research
Verified
Journal Article
Open access
PDF file
YTYu-Hung Tian
Yu-Hung Tian
KCKuan-Lin Chen
Kuan-Lin Chen
KKKevin Chi-Yun Kao
Kevin Chi-Yun Kao
PWPai-Han Wang
Pai-Han Wang
CCChao-Ming Chen
Chao-Ming Chen
WCWei-Ming Chen
Wei-Ming Chen
Osteosarcoma occurs most commonly during adolescence, a period of active skeletal growth. Beyond concerns regarding survival, patients and their families o